(Q34496400)

English

The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

0 references

Hans-Jürgen Möller

11

object named as

Möller HJ

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

author name string

Müller N

1

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Schwarz MJ

2

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Dehning S

3

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Douhe A

4

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Cerovecki A

5

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Goldstein-Müller B

6

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Spellmann I

7

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Hetzel G

8

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Maino K

9

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Kleindienst N

10

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Arolt V

12

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Riedel M

13

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

language of work or name

0 references

publication date

21 February 2006

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Molecular Psychiatry

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

680-684

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

The global burden of disease, 1990–2020

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001805

21 January 2018

Low levels of circulating inflammatory cytokines--do they affect human brain functions?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001805

21 January 2018

Correlation between sICAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon-alpha.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001805

21 January 2018

Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001805

21 January 2018

Inflammatory markers in major depression and melancholia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001805

21 January 2018

The inflammatory response system and the availability of plasma tryptophan in patients with primary sleep disorders and major depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001805

21 January 2018

Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001805

21 January 2018

Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001805

21 January 2018

Actions of the tricyclic antidepressant clomipramine on responses to pressor agents. Interactions with prostaglandin E2

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001805

21 January 2018

Cytokine-induced sickness behavior: where do we stand?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001805

21 January 2018

Intracerebral administration of Mycoplasma fermentans produces sickness behavior: role of prostaglandins.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001805

21 January 2018

Improved control of osteoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in Spain.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001805

21 January 2018

A rating scale for depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001805

21 January 2018

Reboxetine: the first selective noradrenaline re-uptake inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001805

21 January 2018

The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001805

21 January 2018

Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001805

21 January 2018

COX-2 inhibitors as adjunctive therapy in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001805

21 January 2018

Beyond the Kraepelinean dichotomy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001805

21 January 2018

Inhibition of COX-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001805

21 January 2018

Inhibition of COX-2 by celecoxib enhances glucocorticoid receptor function

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001805

21 January 2018

Effect of rofecoxib on nociception and the serotonin system in the rat brain

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001805

21 January 2018

CSF Prostaglandin Levels in Depressed and Schizophrenic Patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001805

21 January 2018

Multiple sclerosis and depression: influence of interferon beta therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001805

7 January 2021

based on heuristic

inferred from DOI database lookup

Investigations of the cellular immunity during depression and the free interval: evidence for an immune activation in affective psychosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001805

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytokine production and treatment response in major depressive disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001805

7 January 2021

based on heuristic

inferred from DOI database lookup

Depression, immunocompetence, and prostaglandins of the E series

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001805

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased level of salivary prostaglandins in patients with major depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001805

7 January 2021

based on heuristic

inferred from DOI database lookup

Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001805

7 January 2021

based on heuristic

inferred from DOI database lookup

Fluoxetine and amitriptyline inhibit nitric oxide, prostaglandin E2, and hyaluronic acid production in human synovial cells and synovial tissue cultures

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001805

7 January 2021

based on heuristic

inferred from DOI database lookup

Lipopolysaccharide injected into the cerebral ventricle evokes fever through induction of cyclooxygenase-2 in brain endothelial cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001805

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.MP.4001805

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34496400&oldid=2196710758"